Navigation Links
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Date:12/28/2007

iance may receive milestone payments on future sales.

Zensana(TM) (ondansetron HCI) Oral Spray:

In August 2007, Par Pharmaceutical, Inc. acquired the North American commercial rights to Zensana(TM) from Hana Biosciences, Inc. Ondansetron is used to prevent nausea and vomiting after chemotherapy, radiation and surgery. Following successful development and approval, Zensana(TM) could be among the first in its class of 5-HT3 antagonist anti-emetic therapies to be available in an oral spray form.

Under a development agreement with Novadel Pharma, Inc., Par has completed its reformulation of Zensana(TM) and is preparing for the requisite studies to reconfirm the product's pharmacokinetic profile and confirm stability acceptability. These studies are expected to be completed by the end of 2008 with an NDA to be filed shortly thereafter.

In return for the North American commercial rights to Zensana(TM), Par made a $5 million equity investment in Hana. In addition, Hana may receive future milestone payments and royalties on future sales of the product.

John MacPhee, president of Strativa Pharmaceuticals, said, "We are excited about our current pipeline and look forward to bringing these innovative treatment options to patients and their healthcare providers. In addition, we will continue to pursue products that leverage our commercial presence and expertise in supportive care in oncology and AIDS."

About Strativa

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Supported by Par's financial and organizational capabilities including substantial cash resources, Strativa Pharmaceuticals is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for introduction and to help ensure their success after
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Introducing Strativa Pharmaceuticals
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
(Date:12/15/2014)... Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) ... supplier of crop seeds in China , ... fiscal year 2014 ended September 30, 2014, before the market ... will host a teleconference on January 8, 2015, at 8:00 ... time to discuss the results. To participate in the call, ...
(Date:12/13/2014)... - MaRS and Virgin Unite Canada, the non-profit foundation of ... to support Canadian entrepreneurs tackling social and environmental challenges. Today, ... the MaRS Centre to announce the new partnership, which includes ... fund has $1 million in seed capital provided by Virgin ... Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... million, -- Quarterly Net Income Increases 76.5% to ... YORK and HAIKOU, Hainan, China, May 2 /Xinhua-PRNewswire-FirstCall/,-- ... Board: CPHI),which develops, manufactures, and markets generic and ... results,for the first quarter of 2008., ...
... May 2 eResearchTechnology, Inc.,(eRT), (Nasdaq: ... (ECG) collection and interpretation services,announced today that ... and,Chief Executive Officer, and Richard Baron, the ... at the Deutsche Bank 33rd Annual,Healthcare Conference ...
... 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... for the early,detection of diseases and personalized ... for the first quarter ended March 31,2008., ... of the key milestones,necessary to support the ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 4China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 5China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 6China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 7China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 8China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 9eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008 2GeneNews Announces First Quarter Results 2GeneNews Announces First Quarter Results 3GeneNews Announces First Quarter Results 4GeneNews Announces First Quarter Results 5GeneNews Announces First Quarter Results 6GeneNews Announces First Quarter Results 7GeneNews Announces First Quarter Results 8
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... June 09, 2009 / b3c newswire / - ... Netherlands Organisation for Applied Scientific Research TNO today announced ... further develop Amarna’s viral gene delivery platform SVac ... for the manufacture, formulation and testing of viral gene ...
... axial complex of sea urchins ( Echinoidea ), an ... that group of marine invertebrates there exists a structural ... in BioMed Central,s open access journal Frontiers in ... structural data available on a given organ in combination ...
... Merck Irving S. Sigal Memorial Award is being presented ... Infectious Disease Initiative at the Broad Institute of MIT ... Medicine at Harvard Medical School. Sponsored by Merck Research ... presented in memory of Irving S. Sigal, who was ...
Cached Biology News:Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Glutathione Agarose Beads 10 ml...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Biology Products: